Skip to main content
Top
Published in: Breast Cancer Research and Treatment 2/2016

01-07-2016 | Epidemiology

Impact of a prior diagnosis of DCIS on survival from invasive breast cancer

Authors: Victoria Sopik, Javaid Iqbal, Ping Sun, Steven A. Narod

Published in: Breast Cancer Research and Treatment | Issue 2/2016

Login to get access

Abstract

A diagnosis of invasive breast cancer after DCIS can be described as a new primary cancer or as a local invasive recurrence. It is of interest to determine if, among women with early-stage breast cancer, a past history of DCIS influences survival. We retrieved the records of 306,249 women diagnosed with stage I or stage II breast cancer between 2004 and 2012, in the surveillance, epidemiology, and end results registries database, of whom 5395 had a previous diagnosis of DCIS. For each patient, we extracted information on the year of diagnosis, age at diagnosis, tumor size, nodal status, grade, estrogen receptor status, type of surgery (lumpectomy/mastectomy), use of radiotherapy (no/yes), prior DCIS (no/yes), cause of death, and follow-up time. For each case with prior DCIS, we recorded information on the year of diagnosis of DCIS, laterality of DCIS, and treatments received for DCIS. We matched 3979 patients with a prior DCIS to 3979 patients without a prior DCIS, according to the various prognostic features of the invasive cancer. We estimated the risk of death from breast cancer for patients with invasive ductal carcinoma, with and without a prior diagnosis of DCIS. We identified 306,249 women with stage I/II breast cancer, of whom 2335 had a prior ipsilateral DCIS and 3060 had a prior contralateral DCIS. Breast cancer-specific survival at 9 years was 94.6 % for patients with a prior DCIS (ipsilateral or contralateral) and was 95.2 % for patients with no prior DCIS (p = 0.32). In a matched analysis (3979 matched pairs), the hazard ratio for death from breast cancer for patients with a prior ipsilateral DCIS, compared to patients with no prior DCIS, was 0.91 (95 % CI = 0.49–1.68; p = 0.75). A prior diagnosis of ipsilateral DCIS does not impact upon the prognosis of women with early-stage invasive breast cancer. This suggests that primary breast cancers and local invasive recurrences following DCIS are similar conditions and should be treated in the same way.
Literature
1.
go back to reference Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ (eds) (2012) WHO classification of tumours of the breast, 4th edn. IARC, Lyon Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ (eds) (2012) WHO classification of tumours of the breast, 4th edn. IARC, Lyon
2.
go back to reference Arvold ND, Punglia RS, Hughes ME et al (2012) Pathologic characteristics of second breast cancers after breast conservation for ductal carcinoma in situ. Cancer 118(24):6022–6030CrossRefPubMedPubMedCentral Arvold ND, Punglia RS, Hughes ME et al (2012) Pathologic characteristics of second breast cancers after breast conservation for ductal carcinoma in situ. Cancer 118(24):6022–6030CrossRefPubMedPubMedCentral
3.
go back to reference Lee LA, Silverstein MJ, Chung CT et al (2006) Breast cancer-specific mortality after invasive local recurrence in patients with ductal carcinoma-in situ of the breast. Am J Surg 192:416–419CrossRefPubMed Lee LA, Silverstein MJ, Chung CT et al (2006) Breast cancer-specific mortality after invasive local recurrence in patients with ductal carcinoma-in situ of the breast. Am J Surg 192:416–419CrossRefPubMed
4.
go back to reference Huang E, Bucholz TA, Meric F et al (2002) Classifying local disease recurrences after breast conservation therapy based on location and histology: new primary tumours have more favourable outcomes than true local disease recurrences. Cancer 95(10):2059–2067CrossRefPubMed Huang E, Bucholz TA, Meric F et al (2002) Classifying local disease recurrences after breast conservation therapy based on location and histology: new primary tumours have more favourable outcomes than true local disease recurrences. Cancer 95(10):2059–2067CrossRefPubMed
5.
go back to reference Fisher B, Anderson S, Bryant J et al (2002) Twenty-year follow-up of a randomized trial comparing total mastectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347(16):1233–1241CrossRefPubMed Fisher B, Anderson S, Bryant J et al (2002) Twenty-year follow-up of a randomized trial comparing total mastectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347(16):1233–1241CrossRefPubMed
6.
go back to reference Veronesi U, Cascinelli N, Mariani L et al (2002) Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347(16):1227–1232CrossRefPubMed Veronesi U, Cascinelli N, Mariani L et al (2002) Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347(16):1227–1232CrossRefPubMed
7.
go back to reference Narod SA, Iqbal J, Giannakeas V, Sopik V, Sun P (2015) Breast cancer mortality after a diagnosis of ductal carcinoma in situ. JAMA Oncol 1(7):888–896CrossRefPubMed Narod SA, Iqbal J, Giannakeas V, Sopik V, Sun P (2015) Breast cancer mortality after a diagnosis of ductal carcinoma in situ. JAMA Oncol 1(7):888–896CrossRefPubMed
8.
go back to reference Falk R, Hofvind S, Skaane P, Haldorsen T (2011) Second events following ductal carcinoma in situ of the breast: a register-based cohort study. Breast Cancer Res Treat 129:929–938CrossRefPubMed Falk R, Hofvind S, Skaane P, Haldorsen T (2011) Second events following ductal carcinoma in situ of the breast: a register-based cohort study. Breast Cancer Res Treat 129:929–938CrossRefPubMed
9.
go back to reference Warnberg F, garmo H, Emdin S et al (2014) Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS trial. J Clin Oncol 32:3613–3618CrossRefPubMed Warnberg F, garmo H, Emdin S et al (2014) Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS trial. J Clin Oncol 32:3613–3618CrossRefPubMed
10.
go back to reference Donker M, Litiere S, Werutsky G et al (2013) Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. J Clin Oncol 31:4054–4059CrossRefPubMed Donker M, Litiere S, Werutsky G et al (2013) Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. J Clin Oncol 31:4054–4059CrossRefPubMed
11.
go back to reference Stuart KE, Houssami N, Taylor R, Hayen A, Boyages J (2015) Long-term outcomes of ductal carcinoma in situ of the breast: a systematic review, meta-analysis and meta-regression analysis. BMC Cancer 15:890CrossRefPubMedPubMedCentral Stuart KE, Houssami N, Taylor R, Hayen A, Boyages J (2015) Long-term outcomes of ductal carcinoma in situ of the breast: a systematic review, meta-analysis and meta-regression analysis. BMC Cancer 15:890CrossRefPubMedPubMedCentral
12.
go back to reference Sopik V, Nofech-Moses S, Sun P (2016) The relationship between local recurrence and death in early-stage breast cancer. Breast Cancer Res Treat 155(1):175–185CrossRefPubMed Sopik V, Nofech-Moses S, Sun P (2016) The relationship between local recurrence and death in early-stage breast cancer. Breast Cancer Res Treat 155(1):175–185CrossRefPubMed
13.
go back to reference Smith TE, Lee D, Turner B, Carter D, Haffty B (2000) True recurrence versus new primary breast tumour relapse: an analysis of clinical and pathologic differences and their implications in natural history, prognoses, and therapeutic management. Int J Radiat Oncol Biol Phys 48(5):1281–1289CrossRefPubMed Smith TE, Lee D, Turner B, Carter D, Haffty B (2000) True recurrence versus new primary breast tumour relapse: an analysis of clinical and pathologic differences and their implications in natural history, prognoses, and therapeutic management. Int J Radiat Oncol Biol Phys 48(5):1281–1289CrossRefPubMed
14.
go back to reference Dent R, Valentini A, Hanna W et al (2014) Factors associated with breast cancer mortality after local recurrence. Curr Oncol 21(3):418–425CrossRef Dent R, Valentini A, Hanna W et al (2014) Factors associated with breast cancer mortality after local recurrence. Curr Oncol 21(3):418–425CrossRef
15.
go back to reference Engel J, Eckel R, Kerr J et al (2003) The process of metastasisation for breast cancer. Eur J Cancer 39:1794–1806CrossRefPubMed Engel J, Eckel R, Kerr J et al (2003) The process of metastasisation for breast cancer. Eur J Cancer 39:1794–1806CrossRefPubMed
16.
go back to reference Anderson S, Wapnir I, Dignam J et al (2009) Prognosis after ipsilateral breast tumour recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five national surgical adjuvant breast and bowel project protocols of node-negative breast cancer. J Clin Oncol 27:2466–2473CrossRefPubMedPubMedCentral Anderson S, Wapnir I, Dignam J et al (2009) Prognosis after ipsilateral breast tumour recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five national surgical adjuvant breast and bowel project protocols of node-negative breast cancer. J Clin Oncol 27:2466–2473CrossRefPubMedPubMedCentral
17.
go back to reference Wapnir I, Anderson S, Mamounas E et al (2006) Prognosis after ipsilateral breast tumour recurrence and locoregional recurrences in five national surgical adjuvant breast and bowel project protocols of node-positive breast cancer. J Clin Oncol 24:2028–2037CrossRefPubMed Wapnir I, Anderson S, Mamounas E et al (2006) Prognosis after ipsilateral breast tumour recurrence and locoregional recurrences in five national surgical adjuvant breast and bowel project protocols of node-positive breast cancer. J Clin Oncol 24:2028–2037CrossRefPubMed
18.
go back to reference Witteveen A, Kwast A, Sonke G, Ijzerman M, Siesling S (2015) Survival after locoregional recurrence or second primary breast cancer: impact of the disease-free interval. PLoS One 10(4):e0120832CrossRefPubMedPubMedCentral Witteveen A, Kwast A, Sonke G, Ijzerman M, Siesling S (2015) Survival after locoregional recurrence or second primary breast cancer: impact of the disease-free interval. PLoS One 10(4):e0120832CrossRefPubMedPubMedCentral
19.
go back to reference Yi M, Buchholz T, Meric-Bernstam F et al (2011) Classification of ipsilateral breast tumour recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning. Ann Surg 253(3):572–579CrossRefPubMedPubMedCentral Yi M, Buchholz T, Meric-Bernstam F et al (2011) Classification of ipsilateral breast tumour recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning. Ann Surg 253(3):572–579CrossRefPubMedPubMedCentral
Metadata
Title
Impact of a prior diagnosis of DCIS on survival from invasive breast cancer
Authors
Victoria Sopik
Javaid Iqbal
Ping Sun
Steven A. Narod
Publication date
01-07-2016
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2016
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-016-3894-9

Other articles of this Issue 2/2016

Breast Cancer Research and Treatment 2/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine